Skip to main content

Clinical outcomes after percutaneous coronary intervention in non-dialysis patients with acute coronary syndrome and advanced renal dysfunction

Clinical and Experimental Nephrology volume 24, pages 339–348 (2020)Cite this article

Abstract

Background

Data about the clinical outcomes of ACS patients with advanced renal dysfunction (estimated glomerular filtration rate < 30 mL/min/1.73 m2) following percutaneous coronary intervention (PCI) are limited.

Methods

We examined the data obtained from 194 ACS patients with non-dialysis advanced renal dysfunction who underwent PCI at five hospitals. The primary composite endpoint was the incidence of major adverse cardiac and cerebrovascular events (MACCE: all-cause death, myocardial infarction, and ischemic stroke).

Results

Eighty patients (41.2%) were diagnosed with ST-elevation myocardial infarction (STEMI), and 117 patients (58.8%) with non-ST-elevation ACS (NSTE-ACS). Overall patients were followed for a median of 657.5 days. Cumulative incidence of MACCE at median follow-up was 32.3% (45.4% for STEMI and 23.4% for NSTE-ACS). Kaplan–Meier analysis demonstrated that patients in the STEMI group had significantly higher incidence of MACCE than those in the non-STEMI and unstable angina group (Log-rank p < 0.001). In-hospital MACCE rate was higher in the STEMI group than in the NSTE-ACS group, whereas post-discharge MACCE rate was comparable between the two groups. In the multivariate analysis, STEMI and Killip classification ≥ 2 were associated with in-hospital MACCE. On the other hand, body mass index and serum albumin at admission were independent predictors of post-discharge MACCE.

Conclusions

Short- and long-term prognoses following PCI in non-dialysis patients with ACS and advanced renal dysfunction is still unfavorable. STEMI and Killip classification ≥ 2 were independent predictors for in-hospital MACCE, and body mass index and serum albumin were for post-discharge MACCE.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. Rott D, Klempfner R, Goldenberg I, Matezky S, Elis A. Temporal trends in the outcomes of patients with acute myocardial infarction associated with renal dysfunction over the past decade. Eur J Intern Med. 2016;29:88–92.

    Article  Google Scholar 

  2. Dohi T, Kasai T, Miyauchi K, et al. Prognostic impact of chronic kidney disease on 10-year clinical outcomes among patients with acute coronary syndrome. J Cardiol. 2012;60:439–42.

    Article  Google Scholar 

  3. Saltzman AJ, Stone GW, Claessen BE, et al. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. JACC Cardiovasd Interv. 2011;4:1011–9.

    Article  Google Scholar 

  4. Kimura K, Kimura T, Ishihara M, et al. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ J. 2019;83:1085–96.

    CAS  Article  Google Scholar 

  5. Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of European Society of Cardiology (ESC). Eur Heart J. 2016;37:267–315.

    CAS  Article  Google Scholar 

  6. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;130:e344–426.

    PubMed  Google Scholar 

  7. Medi C, Montalescot G, Budaj A, et al. Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block: GRACE (Global Registry of Acute Coronary Events). JACC Cardiovasc Interv. 2009;2:26–33.

    Article  Google Scholar 

  8. Shuvy M, Chen S, Vorobeichik D, et al. Temporal trends in management and outcomes of patients with acute coronary syndrome according to renal function. Int J Cardiol. 2017;232:48–52.

    Article  Google Scholar 

  9. Spinler SA, Mahaffey KW, Fallup D, et al. Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. Int J Cardiol. 2010;144:36–41.

    Article  Google Scholar 

  10. Ohno Y, Maekawa Y, Miyata H, et al. Impact of periprocedural bleeding on incidence of contrast-induced acute kidney injury in patients treated with percutaneous coronary intervention. J Am Coll Cardiol. 2013;62:1260–6.

    Article  Google Scholar 

  11. Smilowitz NR, Gupta N, Guo Y, Mauricio R, Bangalore S. Management and outcomes of acute myocardial infarction in patients with chronic kidney disease. Int J Cardiol. 2017;227:1–7.

    Article  Google Scholar 

  12. Bhatia S, Arora S, Bhatia SM, et al. Non-ST-segment elevation myocardial infarction among patients with chronic kidney disease: a propensity score-matched comparison of percutaneous coronary intervention versus conservative management. J Am Heart Assoc. 2018. https://doi.org/10.1161/JAHA.117.007920.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Shaw C, Nitsch D, Lee J, Fogarty D, Sharpe CC. Impact of an early invasive strategy versus conservative strategy for unstable angina and non-ST-elevation acute coronary syndrome in patients with chronic kidney disease: a systematic review. PLoS ONE. 2016. https://doi.org/10.1371/journal.pone.0153478.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Negishi Y, Tanaka A, Ishii H, et al. Contrast-induced nephropathy and long-term clinical outcomes following percutaneous coronary intervention in patients with advanced renal dysfunction (estimated glomerular filtration rate %3c 30 ml/min/1.73 m2). Am J Cardiol. 2019;123:361–7.

    Article  Google Scholar 

  15. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.

    CAS  Article  Google Scholar 

  16. Palmerini T, Della Riva D, Benedetto U, et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11,473 patients. Eur Heart J. 2017;38:1034–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Maini R, Wong DB, Addison D, Chiang E, Weisbord SD, Jneid H. Persistent underrepresentation of kidney disease in randomized, controlled trials of cardiovascular disease in the contemporary era. J Am Soc Nephrol. 2018;29:2782–6.

    Article  Google Scholar 

  18. Yew RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362:2155–65.

    Article  Google Scholar 

  19. Takii T, Yasuda S, Takahashi J, et al. Trends in acute myocardial infarction incidence and mortality over 30 years in Japan: report from the MIYAGI-AMI registry study. Circ J. 2010;74:93–100.

    Article  Google Scholar 

  20. Daida H, Miyauchi K, Ogawa H, et al. Management and two-tear long-term clinical outcome of acute coronary syndrome in Japan: prevention of atherothrombotic incidents following ischemic coronary attack (PACIFIC) registry. Circ J. 2013;77:934–43.

    CAS  Article  Google Scholar 

  21. Kovesdy CP, Kalantar-Zadeh K. Why is protein-energy wasting associated with mortality in chronic kidney disease? Semin Nephrol. 2009;29:3–14.

    CAS  Article  Google Scholar 

  22. Ishii H, Takahashi H, Ito Y, et al. The association of ankle brachial index, protein-energy wasting, and inflammation status with cardiovascular mortality in patients on chronic hemodialysis. Nutrients. 2017. https://doi.org/10.3390/nu9040416.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Wada H, Dohi T, Miyauchi K, et al. Independent and combined effects of serum albumin and c-reactive protein on long-term outcomes of patients undergoing percutaneous coronary intervention. Circ J. 2017;81:1293–300.

    CAS  Article  Google Scholar 

  24. Held C, White HD, Stewart RAH, et al. Inflammatory biomarkers interleukin-6 and c-reactive protein and outcomes in stable coronary heart disease: experience from the STABILITY (stabilization of atherosclerotic plaque by initiation of Darapladib therapy) trial. J Am Heart Assoc. 2017. https://doi.org/10.1161/JAHA.116.005077.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014;114:1867–79.

    CAS  Article  Google Scholar 

  26. Westman PC, Lipinski MJ, Luger D, et al. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol. 2016;67:2050–60.

    Article  Google Scholar 

  27. Kutul A, Murat SN, Yarlioglues M, et al. Usefulness of serum albumin concentration to predict high coronary SYNTAX score and in-hospital mortality in patients with acute coronary syndrome. Angiology. 2016;67:34–40.

    Article  Google Scholar 

  28. O’Brien EC, Fosbol EL, Peng SA, et al. Association of body mass index and long-term outcomes in older patients with non-ST-segment-elevation myocardial infarction: results from the CRUSADE Registry. Circ Cardiovasc Qual Outcomes. 2014;7:102–9.

    Article  Google Scholar 

  29. Plakht Y, Gilutz H, Shiyovich A. Decreased admission serum albumin level is an independent predictor of long-term mortality in hospital survivors of acute myocardial infarction. Soraka Acute Myocardial Infarction II (SAMI II) project. Int J Cardiol. 2016;219:20–4.

    Article  Google Scholar 

  30. Gonzalez-Pacheco H, Amezcua-Guerra LM, Sandoval J, et al. Prognostic implications of serum albumin levels in patients with acute coronary syndromes. Am J Cardiol. 2017;119:951–8.

    CAS  Article  Google Scholar 

  31. Deedwania P, Acharya T, Kotak K, et al. Compliance with guideline-directed medical therapy in diabetic patients admitted with acute coronary syndrome: findings from the American Heart Association’s get with the guidelines-coronary artery disease (GWTG-CAD) program. Am Heart J. 2017;187:78–877.

    Article  Google Scholar 

  32. Lahoud R, Howe M, Krishnan SM, Zacharias S, Jackson EA. Effect of use of combination evidence-based medical therapy after acute coronary syndromes on long-term outcomes. Am J Cardiol. 2012;109:159–64.

    Article  Google Scholar 

  33. Ge Z, Baber U, Claessen BE, et al. The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheter Cardiovasc Interv. 2019;93:E112–E11919.

    Article  Google Scholar 

  34. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010;121:357–65.

    CAS  Article  Google Scholar 

  35. Reddan DN, Szczech L, Bhapkar MV, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial Transpl. 2005;20:2105–12.

    Article  Google Scholar 

  36. Natsuaki M, Furusawa Y, Morimoto T, Sakata R, Kimura T, CREDO-Kyoto PCI/CABG Registry Cohort-2 investigators. Renal function and effect of statin therapy on cardiovascular outcomes in patients undergoing coronary revascularization (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). Am J Cardiol. 2012;110:1168–77.

    Article  Google Scholar 

  37. Ishii M, Hokimoto S, Akasaka T, Fujimoto K, Miyao Y, Kakita K, et al. Differential effects of strong and regular statins on the clinical outcomes of patients with chronic kidney disease following coronary stent implantation—the Kumamoto Intervention Conference Study (KICS) registry. Circ J. 2015;79:1115–24.

    Article  Google Scholar 

Download references

Author information

Affiliations

  1. Cardiovascular Center, Anjo Kosei Hospital, 28 Higashi-Hirokute, Anjo, 446-8602, Japan

    Yusuke Uemura, Shinji Ishikawa, Kenji Takemoto & Masato Watarai

  2. Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Yosuke Negishi, Akihito Tanaka, Hideki Ishii & Toyoaki Murohara

  3. Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan

    Kensuke Takagi, Naoyuki Yoshioka & Itsuro Morishima

  4. Department of Cardiology, Ichinomiya Municipal Hospital, Ichinomiya, Japan

    Norio Umemoto & Naoki Shibata

  5. Department of Cardiology, Tosei General Hospital, Seto, Japan

    Yosuke Inoue & Hiroshi Asano

Authors
  1. Yusuke Uemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinji Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenji Takemoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yosuke Negishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akihito Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kensuke Takagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naoyuki Yoshioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Norio Umemoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yosuke Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Itsuro Morishima
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Naoki Shibata
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hiroshi Asano
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hideki Ishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Masato Watarai
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Toyoaki Murohara
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

N-registry investigators

Corresponding author

Correspondence to Yusuke Uemura.

Ethics declarations

Conflict of interest

H.I. received lecture fees from Astellas Pharma Inc., Astrazeneca Inc., Daiichi-Sankyo Pharma Inc., and MSD K. K. T.M. received lecture fees from Bayel Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kowa Co., Ltd., MSD K. K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K. K., Pfizer Japan Inc., Sanofi-aventis K. K., and Takeda Pharmaceutical Co., Ltd. T.M. received unrestricted research grant for Department of Cardiology, Nagoya University Graduate School of Medicine from Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kowa Co., Ltd., MSD K. K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K. K., Otsuka Pharma Ltd., Pfizer Japan Inc., Sanofi-aventis K. K., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd.

Human and animal rights

This study was performed in accordance with the Declaration of Helsinki, and the research protocol was approved by the ethics committees of research institute (Approval no. 2017–0275). Because of a retrospective cohort study, informed consent from individual patients was waived.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Fig. 1. Study population

About this article

Verify currency and authenticity via CrossMark

Cite this article

Uemura, Y., Ishikawa, S., Takemoto, K. et al. Clinical outcomes after percutaneous coronary intervention in non-dialysis patients with acute coronary syndrome and advanced renal dysfunction. Clin Exp Nephrol 24, 339–348 (2020). https://doi.org/10.1007/s10157-019-01839-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-019-01839-x

Keywords

  • Acute coronary syndrome
  • Advanced renal dysfunction
  • Prognosis